Apollo Therapeutics wins KE Deal of the Year
Apollo Therapeutics received recognition at the Praxis Auril KE Awards 2021, picking up Deal of the Year, for attracting major investment to empower a unique, multi-university portfolio-based biopharmaceuticals venture.
The Praxis Auril Awards, which took place through an online ceremony on 18 November 2021, recognises achievements within knowledge exchange across the UK and internationally.
In 2016, UCL, Imperial College London and the University of Cambridge came together with AstraZeneca, GSK and Johnson & Johnson to launch Apollo Therapeutics. It was set up to translate promising therapeutic academic programmes at the three universities into pharma ready projects.
This year, a landmark deal gave Apollo Therapeutics its ability to support and propel the translation of world leading science into patient benefit. The £100m financing, led by Patient Square Capital and supported by Rock Springs Capital, Reimagined Ventures, and the UCL Technology Fund provided Apollo Therapeutics the financial resource to de-risk projects from UCL, Cambridge University and Imperial College London.
The deal relied upon the three universities to collaboratively deploy their commercialisation expertise and it included each partner’s finance, legal, regulatory and business management functions. The deal now allows them all to take their collective ambitions for knowledge exchange one-step further.